{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:44:07Z","timestamp":1760784247869,"version":"3.40.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Italian Ministry of Health"},{"name":"Ricerca Corrente"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.antiviral.2017.03.008","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T15:46:20Z","timestamp":1489851980000},"page":"62-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002\u20132012) of different treatment regimens: The legacy of lamivudine\/adefovir combination treatment"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1821-4248","authenticated-orcid":false,"given":"Donatella","family":"Vincenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0263","authenticated-orcid":false,"given":"Pierluca","family":"Piselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariacarmela","family":"Solmone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpiero","family":"D'Offizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R.","family":"Capobianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-3750","authenticated-orcid":false,"given":"Stefano","family":"Menzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.antiviral.2017.03.008_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jhep.2013.11.024","article-title":"Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients","volume":"60","author":"Berg","year":"2014","journal-title":"J.\u00a0Hepatol."},{"issue":"4","key":"10.1016\/j.antiviral.2017.03.008_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2007.06.011","article-title":"Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials","volume":"47","author":"Borroto-Esoda","year":"2007","journal-title":"J.\u00a0Hepatol."},{"issue":"6","key":"10.1016\/j.antiviral.2017.03.008_bib3","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20723","article-title":"Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir","volume":"41","author":"Brunelle","year":"2005","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.antiviral.2017.03.008_bib4","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/QAD.0b013e32836011c2","article-title":"Tenofovir-based combination therapy for HIV\/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia","volume":"27","author":"Childs","year":"2013","journal-title":"Aids"},{"issue":"2","key":"10.1016\/j.antiviral.2017.03.008_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2005.10.018","article-title":"Virologic response and resistance to adefovir in patients with chronic hepatitis B","volume":"44","author":"Fung","year":"2006","journal-title":"J.\u00a0Hepatol."},{"issue":"8","key":"10.1016\/j.antiviral.2017.03.008_bib6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1177\/135965350601100801","article-title":"Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases","volume":"11","author":"Gerolami","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2017.03.008_bib7","first-page":"95","article-title":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT","volume":"41","author":"Hall","year":"1999","journal-title":"Nucl. Acids. Symp. Ser."},{"issue":"7","key":"10.1016\/j.antiviral.2017.03.008_bib8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/jmv.21505","article-title":"Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B","volume":"81","author":"Iacomi","year":"2009","journal-title":"J.\u00a0Med. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2017.03.008_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3851\/IMP2732","article-title":"Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B","volume":"19","author":"Keskin","year":"2014","journal-title":"Antivir. Ther."},{"issue":"1","key":"10.1016\/j.antiviral.2017.03.008_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0000000000000126","article-title":"Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort","volume":"66","author":"Kim","year":"2014","journal-title":"J.\u00a0Acquir Immune Defic. Syndr."},{"issue":"10","key":"10.1016\/j.antiviral.2017.03.008_bib11","doi-asserted-by":"crossref","first-page":"E404","DOI":"10.1111\/j.1469-0691.2012.03951.x","article-title":"Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing","volume":"18","author":"Ko","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"issue":"2","key":"10.1016\/j.antiviral.2017.03.008_bib12","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.04454-14","article-title":"Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.antiviral.2017.03.008_bib13","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"issue":"4 Suppl.\u00a0S1","key":"10.1016\/j.antiviral.2017.03.008_bib15","first-page":"1045A","article-title":"Characterization of multidrug-resistant HBV strains from 40 Chinese hepatitis B patients experienced long-term treatment of nucleos(t)ide analogs","volume":"54","author":"Liu","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.antiviral.2017.03.008_bib14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/liv.12343","article-title":"HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D","volume":"34","author":"Liu","year":"2014","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.antiviral.2017.03.008_bib16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jhep.2005.11.036","article-title":"Cellular and virological mechanisms of HBV drug resistance","volume":"44","author":"Locarnini","year":"2006","journal-title":"J.\u00a0Hepatol."},{"issue":"1","key":"10.1016\/j.antiviral.2017.03.008_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.antiviral.2017.03.008_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jinf.2015.09.038","article-title":"Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones","volume":"72","author":"Murakami","year":"2016","journal-title":"J.\u00a0Infect."},{"issue":"6","key":"10.1016\/j.antiviral.2017.03.008_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2012.01602.x","article-title":"First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice","volume":"19","author":"Pol","year":"2012","journal-title":"J.\u00a0Viral Hepat."},{"issue":"3","key":"10.1016\/j.antiviral.2017.03.008_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","article-title":"In\u00a0vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents","volume":"12","author":"Qi","year":"2007","journal-title":"Antivir. Ther."},{"issue":"4","key":"10.1016\/j.antiviral.2017.03.008_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/135965350901400416","article-title":"Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B","volume":"14","author":"Santantonio","year":"2009","journal-title":"Antivir. Ther."},{"issue":"12","key":"10.1016\/j.antiviral.2017.03.008_bib22","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/molbev\/mst197","article-title":"MEGA6: molecular evolutionary genetics analysis version 6.0","volume":"30","author":"Tamura","year":"2013","journal-title":"Mol. Biol. Evol."},{"issue":"9","key":"10.1016\/j.antiviral.2017.03.008_bib23","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.antiviral.2017.03.008_bib24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.antiviral.2017.03.008_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van Bommel","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.antiviral.2017.03.008_bib26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3851\/IMP2307","article-title":"Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy","volume":"17","author":"van Bommel","year":"2012","journal-title":"Antivir. Ther."},{"issue":"3","key":"10.1016\/j.antiviral.2017.03.008_bib27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2006.11.016","article-title":"Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient","volume":"46","author":"Villet","year":"2007","journal-title":"J.\u00a0Hepatol."},{"issue":"1","key":"10.1016\/j.antiviral.2017.03.008_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jviromet.2009.02.027","article-title":"A\u00a0sensitive direct sequencing assay based on nested PCR for the detection of HBV polymerase and surface glycoprotein mutations","volume":"159","author":"Vincenti","year":"2009","journal-title":"J.\u00a0Virol. Methods"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216304570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216304570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T17:01:15Z","timestamp":1658854875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216304570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":28,"alternative-id":["S0166354216304570"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.03.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002\u20132012) of different treatment regimens: The legacy of lamivudine\/adefovir combination treatment","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}